Literature DB >> 22015112

A toolbox to study liver stage malaria.

Miguel Prudêncio1, Maria M Mota, António M Mendes.   

Abstract

The first obligatory phase of mammalian infection by Plasmodium parasites, the causative agents of malaria, occurs in the liver of the host. This stage of Plasmodium infection bears enormous potential for anti-malarial intervention. Recent technological progress has strongly contributed to overcoming some of the long-standing difficulties in experimentally assessing hepatic infection by Plasmodium. Here, we review appropriate infection models and infection assessment tools, and provide a comprehensive description of recent advances in experimental strategies to investigate the liver stage of malaria. These issues are discussed in the context of current challenges in the field to provide researchers with the technical tools that enable effective experimental approaches to study liver stage malaria.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22015112     DOI: 10.1016/j.pt.2011.09.004

Source DB:  PubMed          Journal:  Trends Parasitol        ISSN: 1471-4922


  54 in total

1.  Vancomycin improves Plasmodium yoelii malaria parasite in vitro liver stage cultures by controlling Elizabethkingia anophelis, a bacterium in the microbiome of lab-reared Anopheles mosquitoes.

Authors:  Melanie J Shears; Sean C Murphy
Journal:  Mol Biochem Parasitol       Date:  2020-04-30       Impact factor: 1.759

Review 2.  Advances in molecular genetic systems in malaria.

Authors:  Tania F de Koning-Ward; Paul R Gilson; Brendan S Crabb
Journal:  Nat Rev Microbiol       Date:  2015-06       Impact factor: 60.633

3.  4(1H)-Quinolones with liver stage activity against Plasmodium berghei.

Authors:  Alexis N Lacrue; Fabián E Sáenz; R Matthew Cross; Kenneth O Udenze; Andrii Monastyrskyi; Steven Stein; Tina S Mutka; Roman Manetsch; Dennis E Kyle
Journal:  Antimicrob Agents Chemother       Date:  2012-11-05       Impact factor: 5.191

Review 4.  Of men in mice: the success and promise of humanized mouse models for human malaria parasite infections.

Authors:  Alexis Kaushansky; Sebastian A Mikolajczak; Marissa Vignali; Stefan H I Kappe
Journal:  Cell Microbiol       Date:  2014-03-06       Impact factor: 3.715

Review 5.  Plasmodium species: master renovators of their host cells.

Authors:  Tania F de Koning-Ward; Matthew W A Dixon; Leann Tilley; Paul R Gilson
Journal:  Nat Rev Microbiol       Date:  2016-07-04       Impact factor: 60.633

Review 6.  An expanding toolkit for preclinical pre-erythrocytic malaria vaccine development: bridging traditional mouse malaria models and human trials.

Authors:  Ryan Wj Steel; Stefan Hi Kappe; Brandon K Sack
Journal:  Future Microbiol       Date:  2016-11-18       Impact factor: 3.165

7.  Susceptibility to Plasmodium liver stage infection is altered by hepatocyte polyploidy.

Authors:  Laura S Austin; Alexis Kaushansky; Stefan H I Kappe
Journal:  Cell Microbiol       Date:  2014-03-28       Impact factor: 3.715

8.  Plasmodium berghei EXP-1 interacts with host Apolipoprotein H during Plasmodium liver-stage development.

Authors:  Cláudia Sá E Cunha; Britta Nyboer; Kirsten Heiss; Margarida Sanches-Vaz; Diana Fontinha; Ellen Wiedtke; Dirk Grimm; Jude Marek Przyborski; Maria M Mota; Miguel Prudêncio; Ann-Kristin Mueller
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-30       Impact factor: 11.205

9.  Novel endoperoxide-based transmission-blocking antimalarials with liver- and blood-schizontocidal activities.

Authors:  Daniela Miranda; Rita Capela; Inês S Albuquerque; Patrícia Meireles; Isa Paiva; Fátima Nogueira; Richard Amewu; Jiri Gut; Philip J Rosenthal; Rudi Oliveira; Maria M Mota; Rui Moreira; Francesc Marti; Miguel Prudêncio; Paul M O'Neill; Francisca Lopes
Journal:  ACS Med Chem Lett       Date:  2013-12-20       Impact factor: 4.345

Review 10.  Recent advances in malaria drug discovery.

Authors:  Marco A Biamonte; Jutta Wanner; Karine G Le Roch
Journal:  Bioorg Med Chem Lett       Date:  2013-03-27       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.